SRPT logo

Sarepta Therapeutics, Inc.

SRPT
Healthcare|Biotechnology|US
$17.82
+0.25 (+1.42%)
Tangible Book / Share
$14.15
Graham Number
$6.73
Cash / Share
$8.30

Clinical Trials (59)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT07542314
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
Duchenne Muscular Dystrophy
P4
Recruiting20Open-labelELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics
NCT05881408
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
P3
Active148RCT, Double-blind—
NCT03992430
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
Muscular Dystrophy, Duchenne
P3
Active160RCT, Double-blindEteplirsen
NCT06246513
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
Limb-girdle Muscular Dystrophy
P3
Active17Open-labelSRP-9003, Glucocorticoid
NCT06128564
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
P2
Active13Open-label—
NCT05876780
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
Limb Girdle Muscular Dystrophy
P1
Active6Open-label—
NCT04626674
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Duchenne Muscular Dystrophy
P1
Recruiting83Open-label—
NCT07536061
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Huntington's Disease
P1
Recruiting32RCT, Double-blindSRP-1005, Placebo
NCT03655223
Early Check: Expanded Screening in Newborns
Spinal Muscular Atrophy, Fragile X Syndrome
Active30,000——
NCT04475926
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
Limb-girdle Muscular Dystrophy
Active205——
NCT04708314
An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
P4
Terminated2Open-labelGolodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
NCT05096221
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
P3
Completed126RCT, Double-blind—
NCT05967351
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Duchenne Muscular Dystrophy
P3
By Invite400Open-label—
NCT02500381
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
P3
Completed228RCT, Double-blindSRP-4045, SRP-4053, Placebo
NCT02255552
Study of Eteplirsen in DMD Patients
Duchenne Muscular Dystrophy (DMD)
P3
Completed109Open-labeleteplirsen
NCT03532542
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
P3
Terminated171Open-labelCasimersen, Golodirsen
NCT06952686
A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants
Muscular Dystrophies, Limb-Girdle
P3
Withdrawn—Open-labelSRP-9005, Corticosteroid
NCT03652259
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
Limb-Girdle Muscular Dystrophy, Type 2E
P1P2
Terminated6Open-label—
NCT01976091
A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)
Limb-Girdle Muscular Dystrophy, Type 2D
P1P2
Completed6Open-label—
NCT06131983
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
Muscular Dystrophy, Facioscapulohumeral
P1P2
By Invite60RCT, Double-blindSRP-1001 for Injection, Placebo
NCT02420379
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
P2
Completed33Open-labeleteplirsen
NCT00844597
Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Duchenne Muscular Dystrophy
P1P2
Completed19Open-labelAVI-4658 for Injection
NCT00159250
Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
P1P2
Completed7Single-blindAVI-4658 (PMO)
NCT04179409
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.
Duchenne Muscular Dystrophy
P2
Completed3Open-labelAmondys 45, Exondys 51, Vyondys 53
NCT01396239
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
Duchenne Muscular Dystrophy
P2
Completed12RCT, Double-blindAVI-4658 (Eteplirsen)
NCT03675126
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
Muscular Dystrophy, Duchenne
P1P2
Terminated15Open-labelSRP-5051
NCT02286947
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
Muscular Dystrophy, Duchenne
P2
Completed24Open-labelEteplirsen
NCT03985878
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
Duchenne Muscular Dystrophy
P2
Terminated15Open-labelEteplirsen
NCT00451256
Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)
Cardiovascular Disease, Coronary Artery Bypass
P2
Terminated600RCT, Double-blindAVI-5126
NCT01540409
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
P2
Completed12Open-labelAVI-4658 (Eteplirsen)
NCT00229749
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Hepatitis C
P1P2
Terminated80Open-labelAVI-4065 Injection
NCT03769116
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
Muscular Dystrophy, Duchenne
P1P2
Completed41RCT, Double-blind—
NCT00248066
Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries
Coronary Artery Disease, Coronary Restenosis
P2
Completed50Open-labelRESTEN-MP
NCT06138743
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
Myotonic Dystrophy 1
P1P2
By Invite78RCT, Double-blindSRP-1003 IV Infusion, Placebo IV Infusion, SRP-1003 SC Injection, Placebo SC Injection
NCT03218995
Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping
Duchenne Muscular Dystrophy
P2
Completed15Open-labelEteplirsen
NCT04004065
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Duchenne Muscular Dystrophy
P2
Terminated62RCT, Open-labelVesleteplirsen
NCT03375164
A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
P1P2
Completed4Open-label—
NCT02310906
Phase I/II Study of SRP-4053 in DMD Patients
Duchenne Muscular Dystrophy
P1P2
Completed39RCT, Double-blindPlacebo, SRP-4053
NCT06597656
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
Duchenne Muscular Dystrophy
P1
Terminated3Open-label—
NCT00387283
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
West Nile Virus
P1
Completed14Open-labelAVI-4020 Injection
NCT03375255
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
Muscular Dystrophy, Duchenne
P1
Completed15Open-labelSRP-5051
NCT01353027
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
Ebola Hemorrhagic Fever
P1
Completed30RCT, Double-blindPlacebo, AVI-6002
NCT00091845
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
West Nile Fever
P1
Terminated50Open-labelAVI-4020 Injection
NCT02530905
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Duchenne Muscular Dystrophy
P1
Completed12RCT, Double-blindSRP-4045, Placebo
NCT01566877
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
Marburg Hemorrhagic Fever
P1
Completed40RCT, Double-blindAVI-7288
NCT02710500
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
Dysferlinopathy
P1
Completed2Double-blindrAAVrh74.MHCK7.DYSF.DV
NCT06747273
Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States
Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3
P1
Terminated4Open-labelSRP-9004
NCT00244647
A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis
Coronary Artery Disease, Coronary Stent Restenosis
P1
Terminated40RCT, Single-blindRESTEN-MP
NCT01375985
Safety Study of Single Administration Intravenous Treatment for Influenza
Influenza
P1
Terminated8RCT, Double-blindAVI-7100, Placebo
NCT00381433
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
Encephalitis
P1
Completed12Open-labelAVI-4065 Injection
NCT00343148
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
Neoplasms
P1
Completed6Open-labelAVI-4126 Injection (RESTEN-NG®)
NCT01593072
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Ebola Hemorrhagic Fever
P1
Withdrawn—RCT, Double-blindAVI-7537
NCT01353040
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
Marburg Hemorrhagic Fever
P1
Completed30RCT, Double-blindAVI-6003, Placebo
NCT06241950
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
Duchenne Muscular Dystrophy
P1
Terminated5Open-labelimlifidase
NCT05906251
A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)
Limb Girdle Muscular Dystrophy
P1
Terminated2Open-label—
NCT06581887
Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies
DMD, BMD
Unknown100——
NCT03680365
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Duchenne Muscular Dystrophy, Burden, Dependency
Completed60——
NCT06606340
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
Duchenne Muscular Dystrophy
By Invite300—Eteplirsen, Golodirsen, Casimersen
NCT06270719
An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
By Invite500—Standard of Care